Vivian Y Shi, Erman Güler, Brian Esparza, Jonathan I Silverberg
{"title":"中度至重度特应性皮炎患者从Dupilumab切换到Abrocitinib：播客文章","authors":"Vivian Y Shi, Erman Güler, Brian Esparza, Jonathan I Silverberg","doi":"10.1007/s13555-025-01491-2","DOIUrl":null,"url":null,"abstract":"<p><p>As the number of systemic agents available for the treatment of moderate-to-severe atopic dermatitis (AD) continues to increase, it is likely that patients may need or want to switch from one treatment to another. Owing to differences in the mechanism of action, the systemic agents abrocitinib (an oral Janus kinase 1-selective inhibitor) and dupilumab (an injectable interleukin 4 alpha antagonist) are associated with distinct efficacy and safety profiles. Two recent publications have examined the efficacy and safety of long-term abrocitinib in patients previously treated with dupilumab. In this podcast article, two dermatologists discuss the management of moderate-to-severe AD and highlight factors to consider before changing therapies in the context of these recent studies, focusing on switching from dupilumab to abrocitinib treatment.Below is the link to the electronic supplementary material. Supplementary file1 (MP4 173881 KB).</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2703-2714"},"PeriodicalIF":4.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454849/pdf/","citationCount":"0","resultStr":"{\"title\":\"Switching from Dupilumab to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Podcast Article.\",\"authors\":\"Vivian Y Shi, Erman Güler, Brian Esparza, Jonathan I Silverberg\",\"doi\":\"10.1007/s13555-025-01491-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>As the number of systemic agents available for the treatment of moderate-to-severe atopic dermatitis (AD) continues to increase, it is likely that patients may need or want to switch from one treatment to another. Owing to differences in the mechanism of action, the systemic agents abrocitinib (an oral Janus kinase 1-selective inhibitor) and dupilumab (an injectable interleukin 4 alpha antagonist) are associated with distinct efficacy and safety profiles. Two recent publications have examined the efficacy and safety of long-term abrocitinib in patients previously treated with dupilumab. In this podcast article, two dermatologists discuss the management of moderate-to-severe AD and highlight factors to consider before changing therapies in the context of these recent studies, focusing on switching from dupilumab to abrocitinib treatment.Below is the link to the electronic supplementary material. Supplementary file1 (MP4 173881 KB).</p>\",\"PeriodicalId\":11186,\"journal\":{\"name\":\"Dermatology and Therapy\",\"volume\":\" \",\"pages\":\"2703-2714\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454849/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s13555-025-01491-2\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01491-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Switching from Dupilumab to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Podcast Article.
As the number of systemic agents available for the treatment of moderate-to-severe atopic dermatitis (AD) continues to increase, it is likely that patients may need or want to switch from one treatment to another. Owing to differences in the mechanism of action, the systemic agents abrocitinib (an oral Janus kinase 1-selective inhibitor) and dupilumab (an injectable interleukin 4 alpha antagonist) are associated with distinct efficacy and safety profiles. Two recent publications have examined the efficacy and safety of long-term abrocitinib in patients previously treated with dupilumab. In this podcast article, two dermatologists discuss the management of moderate-to-severe AD and highlight factors to consider before changing therapies in the context of these recent studies, focusing on switching from dupilumab to abrocitinib treatment.Below is the link to the electronic supplementary material. Supplementary file1 (MP4 173881 KB).
期刊介绍：
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
